Telomir completes TELI acquisition for 34.4M shares, consolidates global Telomir-1 rights

Filed April 24, 2026 · Period ending April 22, 2026 · ~1 min read

Key Changes

• high

  Telomir issued 34.4 million restricted common shares to acquire TELI Pharmaceuticals, representing significant dilution to existing shareholders. The deal consolidates all worldwide rights to lead drug candidate Telomir-1 under one company.

  Item 2.01 verify on EDGAR →
• high

  Bayshore Trust provided $1 million cash at closing and committed up to $4 million more tied to FDA milestones, including IND acceptance and Phase 1/2 trial initiation for Telomir-1.

  Item 1.01 verify on EDGAR →
• medium

  The acquisition eliminates prior geographic fragmentation where North American and international rights were held separately, giving Telomir unified control over development and commercialization strategy globally.

  Item 1.01 verify on EDGAR →